ClinicalTrials.gov
ClinicalTrials.gov Menu

Rituximab in Active Ulcerative Colitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00261118
Recruitment Status : Completed
First Posted : December 2, 2005
Last Update Posted : November 6, 2014
Sponsor:
Collaborators:
Hoffmann-La Roche
University of Liverpool
Information provided by (Responsible Party):
Jonathan Michael Rhodes, Royal Liverpool University Hospital

Brief Summary:
There is broad support for the hypothesis that Ulcerative colitis is an auto-immune disease. Rituximab is an antibody protein that removes a subgroup of white blood cells (B lymphocytes) from the circulation. These cells have the capacity to generate the auto-antibodies that typify auto-immune disease. Although Rituximab has been mainly used for treating B lymphocyte malignancies (lymphoma) it has also been used with promising results in Rheumatoid arthritis and has an excellent safety record. This is a small placebo-controlled trial to assess its efficacy and safety in patients with steroid-resistant active ulcerative colitis.

Condition or disease Intervention/treatment Phase
Ulcerative Colitis Drug: Rituximab Phase 2 Phase 3

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Phase 3: Randomised Controlled Trial of Rituximab in Active Ulcerative Colitis
Study Start Date : April 2004
Actual Primary Completion Date : August 2009
Actual Study Completion Date : October 2009

Resource links provided by the National Library of Medicine

Drug Information available for: Rituximab

Arm Intervention/treatment
Active Comparator: 1 (i)
Rituximab 1g in 500 mls of 0.9% normal saline infused into a peripheral vein
Drug: Rituximab
Rituximab 1g in 500 mls Normal Saline Placebo 500 mls Normal Saline
Other Name: MabThera (Roche)

Placebo Comparator: 2 (ii)
500 mls of 0.9% NORMAL SALINE INFUSED INTO A PERIPHERAL VEIN
Drug: Rituximab
Rituximab 1g in 500 mls Normal Saline Placebo 500 mls Normal Saline
Other Name: MabThera (Roche)




Primary Outcome Measures :
  1. Remission defined as a decrease in Mayo score to ≤ 2 points at week 4 [ Time Frame: week 4 ]

Secondary Outcome Measures :
  1. Clinical response defined as a decrease in Mayo score by ≥ 3 points at weeks 4, 8 (partial Mayo score) and 12. [ Time Frame: Week 4, 8 & 12 ]
  2. Remission at weeks 8 and 12. [ Time Frame: week 8 &12 ]
  3. Endoscopic mucosal healing at week 4 and 12 [ Time Frame: Week 4 & 12 ]
  4. Improvement in Inflammatory Bowel Disease specific Quality of Life Index at weeks 4 and 12 [ Time Frame: weeks 4 &12 ]
  5. Histological improvement of disease activity at 4 and 12 weeks compared with baseline. [ Time Frame: week 4 & 12 weeks ]
  6. Treatment tolerability as defined by adverse events. [ Time Frame: all visits ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients over age of 18 years who are capable of providing written informed consent.
  2. Confirmed diagnosis of ulcerative colitis by conventional clinical, endoscopic and histological criteria.
  3. Failure of response to at least two weeks of oral prednisolone 40mg/day.
  4. Active colitis as assessed by a Mayo score [21] of 6-12 inclusive (see Appendix 1)

Exclusion Criteria:

  1. Patients under 18 or unable to give informed consent.
  2. Patients in their first attack of ulcerative colitis.
  3. Patients with severe ulcerative colitis as defined by presence of any of: temperature >37.5oC, pulse rate >100, focal severe or rebound abdominal tenderness, haemoglobin < 10.0g/dl, serum albumin <3.5 g/dl, transverse colon diameter greater than 5.0cms on plain abdominal X ray.
  4. Patients who are pregnant, post partum (<3months) or breast feeding
  5. Patients who are at risk of pregnancy and not using a reliable form of contraception (oral contraceptive and barrier or barrier plus spermicide).
  6. Patients with a stoma
  7. Positive stool culture for pathogens or test for C difficile at screening within 7 days prior to trial entry
  8. Patients for whom a baseline Mayo score can not be reliably calculated: frequent use of laxatives (for proximal constipation) or antimotility agents (for control of diarrhoea)
  9. Any change to maintenance medication for ulcerative colitis: azathioprine or 6-mercaptopurine within previous 3 months or 5-aminosalicylates within previous one month
  10. Any change to rectal therapy for colitis within the previous two weeks.
  11. Participation in other trials in the last 3 months.
  12. Serious intercurrent infection or other clinically important active disease (including renal and hepatic disease)


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00261118


Locations
United Kingdom
Royal Liverpool University Hospital
Liverpool, Merseyside, United Kingdom, L7 8XP
Sponsors and Collaborators
Royal Liverpool University Hospital
Hoffmann-La Roche
University of Liverpool
Investigators
Principal Investigator: Jonathan M Rhodes, MD University of Liverpool

Publications:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Jonathan Michael Rhodes, Invesitgator, Royal Liverpool University Hospital
ClinicalTrials.gov Identifier: NCT00261118     History of Changes
Other Study ID Numbers: RLBUHT R&D 2709
DDX exemption from MRHA ref:-
MF 8000/12794
First Posted: December 2, 2005    Key Record Dates
Last Update Posted: November 6, 2014
Last Verified: November 2014

Keywords provided by Jonathan Michael Rhodes, Royal Liverpool University Hospital:
colitis
rituximab

Additional relevant MeSH terms:
Colitis
Ulcer
Colitis, Ulcerative
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Intestinal Diseases
Pathologic Processes
Inflammatory Bowel Diseases
Rituximab
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents